Zobrazeno 41 - 50
of 369
pro vyhledávání: ''
Publikováno v:
Oncology. 85:128-136
Background: Recent preclinical studies have shown that Forkhead box protein 3 (FOXP3) is an important tumor suppressor gene. The clinical and prognostic implication of FOXP3 expression in breast cancer cells still remains controversial. Methods: We e
Autor:
Jacques Medioni, Gero Kramer, Agnes Maj-Hes, Florian Scotté, Pierre Combe, Reza Elaidi, Stéphane Oudard, Yohan Gornadha, Manuela Schmidinger
Publikováno v:
Oncology. 85:8-13
Objective: To determine if mammalian target of rapamycin (mTOR) inhibitor (everolimus or temsirolimus) rechallenge in the third- or fourth-line setting after sequential use of a vascular endothelial growth factor receptor (VEGF)-targeted agent and an
Autor:
Toshiharu Sakurai, Kazuomi Ueshima, Kinuyo Hatanaka, Masahiro Takita, Satoshi Kitai, Norihisa Yada, Naoshi Nishida, Satoru Hagiwara, Tatsuo Inoue, Tadaaki Arizumi, Yasunori Minami, Masatoshi Kudo
Publikováno v:
Oncology. 84:51-57
Objective: Contrast-enhanced ultrasonography (CEUS) with Sonazoid® and dynamic computed tomography (CT) were used to evaluate radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Local recurrence rate was used as the gold standard of ev
Autor:
Chiun Hsu, Tzeon Jye Chiou, Jennifer Sandoval-Tan, Yu-Yun Shao, Kate Jin, Chia-Tung Shun, Ann-Lii Cheng, Chih-Hung Hsu, Wu Chou Su, Yoon-Koo Kang, Tsai Shen Yang
Publikováno v:
Oncology. 85:44-52
Objectives: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. This multicenter study across several Asian countries was to evaluate the
Autor:
Roopma Wadhwa, Takashi Taketa, Kazuki Sudo, Akihiro Suzuki, Mariela A. Blum, Dipen M. Maru, Ritsuko Komaki, Wayne L. Hofstetter, Jeffrey H. Lee, Brian Weston, Lianchun Xiao, Heath D. Skinner, Jaffer A. Ajani, Manoop S. Bhutani, Stephen G. Swisher, David C. Rice
Publikováno v:
Oncology. 85:95-99
Background: Trimodality therapy (TMT; chemoradiation plus surgery) has level-1 evidence for survival advantage for TMT-eligible esophagogastric cancer patients. Some patients, however, decline surgery after preoperative chemoradiation. The question o
Autor:
Masahiro Takita, Tadaaki Arizumi, Satoru Hagiwara, Toshiharu Sakurai, Tomoyuki Nagai, Satoshi Kitai, Masatoshi Kudo, Tatsuo Inoue, Hiroshi Ida, Naoshi Nishida, Kazuomi Ueshima, Norihisa Yada, Yasunori Minami
Publikováno v:
Oncology. 84:82-87
Objectives: Hepatocellular carcinoma (HCC) is one of the common cancers worldwide. Accurate diagnosis of tumor progression is critical for the appropriate management of HCC. Here, we established a sensitive assay to detect and quantify tumor-derived
Autor:
Susan G. Barr, Steven M. Edworthy, Ann E. Clarke, J L Senécal, Dafna D. Gladman, James E. Hansen, Paul R. Fortin, Christine A. Peschken, Caroline Gordon, Guillermo Ruiz-Irastorza, Anisur Rahman, Søren Jacobsen, John G. Hanly, Edward H. Yelin, William D. Foulkes, Ellen M. Ginzler, Sang Cheol Bae, David A. Isenberg, Rosalind Ramsey-Goldman, Mary Anne Dooley, Lindsey A. Criswell, Lene Dreyer, Yishu Wang, Murray B. Urowitz, M. Petri, Ola Nived, B. Tessier Cloutier, Gunnar Sturfelt, Daniel J. Wallace, Torsten Witte, Sasha Bernatsky, Jeremy A. Labrecque, Susan Manzi
Publikováno v:
Oncology, vol 85, iss 2
Objective: Evidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries. Methods: Information on age, SLE duration, cancer date, and histology
Autor:
Adriana Handra-Luca
Publikováno v:
Oncology. 84:141-149
Objectives: The aim of this study was to determine the clinicopathological significance of blood group expression patterns in patients with surgically resected pancreatic ductal adenocarcinomas. Methods: Pancreatic ductal adenocarcinomas from 459 pat
Autor:
Masakatsu Onozawa, Takashi Kojima, Hiroaki Ikematsu, Atsushi Ohtsu, Miki Ito, Keiko Minashi, Kazuhiro Kaneko, Tomonori Yano, Yusuke Yoda, Hironaga Satake, Yasuhiro Oono, Yoko Yajima, Ryuichi Hayashi
Publikováno v:
Oncology. 84:57-64
Background: Esophageal squamous cell carcinoma (ESCC) is often synchronously accompanied by pharyngeal squamous cell carcinoma (PSCC). However, treatment strategies for these synchronous cancers have not been established. Aim: To evaluate retrospecti
Autor:
Emiliano Calvo, Ji Lin, Carlos Becerra, Matthew D. Galsky, Gayle S. Jameson, Aimee Bence Lin, Karla Hurt, Donald A. Richards, Enaksha R Wickremsinhe, Scott McKane, Scott M. Hynes, F. Braiteh, Robert R. McWilliams, Daniel D. Von Hoff
Publikováno v:
Oncology. 91(5)
Objective: LY2603618, a selective inhibitor of checkpoint kinase 1 (CHK1) and key regulator of the DNA damage checkpoint, may enhance the effects of antimetabolites. This phase I study defined the recommended phase II dose of LY2603618 combined with